SGLT-2i and ARB combination therapy in patients with T2DM and nocturnal hypertension - SGLT-2i and ARB combination therapy in patients with T2DM and nocturnal hypertension (SACRA study)

Jichi Medical University School of Medicine0 个研究点目标入组 176 人开始时间: 2016年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following criteria are not eligible for the study: -History of hypersensitivity to empagliflozin -Breast-feeding, pregnant, possibly pregnant, or plan to become pregnant -Treated with insulin or SU -With renal dysfunction (eGFR<45mL/min/1.73m2) -With liver dysfunction (AST or ALT is 3 times higher than reference value) -Hypotension (systolic blood pressure < 90 mmHg) -With pituitary gland dysfunction or adrenal gland dysfunction -Heart failure patients whose NYHA class is IV -Deemed ineligible for the study due to another reason by investigator -History of diabetic ketoacidosis or diabetic come within 3 months before enrollment -History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment -Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment -Patients received SGLT2 inhibitor within 8 weeks before enrollment

发起方

Jichi Medical University School of Medicine